PCG
BDTX icon

Prosperity Consulting Group’s Black Diamond Therapeutics BDTX Stock Holding History

Prosperity Consulting Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,355
Closed -$24.2K – 639
2026
Q1 		$24.2K Buy
+11,355
New +$27K ﹤0.01% 523

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Prosperity Consulting Group's BDTX Position: Q2 2026 in Review

Prosperity Consulting Group sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 11,355 shares — an estimated $24.2K sold.

Prosperity Consulting Group first reported a position in BDTX in Q1 2026 and held it in 1 quarter. The position peaked at $24.2K in Q1 2026. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Prosperity Consulting Group reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prosperity Consulting Group sold 11,355 Black Diamond Therapeutics shares in Q2 2026, an estimated $24.2K.
  • Prosperity Consulting Group first reported a position in Black Diamond Therapeutics in Q1 2026 and held it in 1 quarter.
  • Prosperity Consulting Group's Black Diamond Therapeutics position peaked at $24.2K in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Prosperity Consulting Group's 13F filing for Q2 2026, filed 13 Aug 2026.